Phaseline

Targets › TLR7

TLR7 (Toll-like receptor 7): drug programs, companies and trials

21 programs from 20 companies in 39 trials: 16 Phase 2, 15 Phase 1, 6 Phase 3, 2 Phase 4; Oncology, Immunology, Infectious disease; next expected readout Dec 2026.

Endosomal receptor that plays a key role in innate and adaptive immunity. Controls host immune response against pathogens through recognition of uridine-containing single strand RNAs (ssRNAs) of viral origin or guanosine analogs. (UniProt, Q9NYK1)

Open in Phaseline: the race on TLR7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Taiwan University HospitalHydroxychloroquine
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 4Graves Ophthalmopathy; Steatohepatitis, NonalcoholicJun 2027
University of OxfordHydroxychloroquine
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 3Pneumonia; COVID-19Jan 2027
NYU Langone HealthHydroxychloroquine
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 3Systemic Lupus Erythematosus; Rheumatic DiseaseJan 2028
Merck KGaAEnpatoran
Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist
TLR8, TLR7Phase 3Systemic Lupus Erythematosus (SLE); Systematic Lupus ErythematosusMay 2029
Eikon TherapeuticsEIK1001
Toll-like receptor 7/8 (TLR 7/8) agonist
TLR7, TLR8Phase 2NSCLC; Advanced Melanoma; Non Small Cell Lung Cancer (Squamous or Non Squamous)Dec 2026
Abramson Cancer Center at Penn MedicineHydroxychloroquine
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 2Breast Cancer Stage IIB; Breast CancerJan 2027
Medical University of South CarolinaHydroxychloroquine
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 2Ovarian Cancer; Prostate Cancer RecurrentMay 2027
Primmune TherapeuticsPRTX007
TLR7 agonist prodrug (prodrug of PRX034)
TLR7Phase 2Melanoma Stage IIIDec 2027
M.D. Anderson Cancer CenterSAR445877
TLR7/8 agonist
TLR7, TLR8Phase 2Non-Small Cell Lung Cancer; Phase 1Feb 2028
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)VIR-2218
TLR7 agonist
TLR7Phase 2Chronic Hepatitis BFeb 2028
Merck KGaAEnpatoran (M5049)
Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist
TLR8, TLR7Phase 2Systemic Lupus ErythematosusAug 2028
Beeline MedicinesAfimetoran (BLN-256)
Toll-like receptor 8 inhibitor; Toll-like receptor 7 inhibitor
TLR8, TLR7Phase 2Systemic Lupus Erythematosus; Cutaneous Lupus Erythematosus (CLE)Apr 2029
National Institute of Allergy and Infectious Diseases (NIAID)3M-052-AF
Toll-like receptor 7/8 agonist
TLR7, TLR8Phase 1Hiv; HIVDec 2026
OX2 TherapeuticsImiquimod
Toll-like receptor 7 agonist
TLR7Phase 1Diffuse Midline Glioma, H3 K27M-Mutant; HSIL, High-Grade Squamous Intraepithelial Lesions; Basal Cell Carcinoma; Cervical Carcinoma …Jan 2027
Bolt BiotherapeuticsBDC-4182
Anti-CLDN18.2 monoclonal antibody conjugated to TLR7/8 dual agonist
CLDN18, TLR7, TLR8Phase 1Gastric Cancer Adenocarcinoma MetastaticMay 2027
West Virginia UniversityHydroxychloroquine sulfate
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 1Adenocarcinoma of the PancreasJun 2027
Ascendis Pharma Oncology DivisionTransCon TLR7/8 Agonist
TLR7/8 agonist with extended half-life via TransCon technology
TLR7, TLR8Phase 1Advanced Solid TumorAug 2027
HighField BiopharmaceuticalsHF50
Liposome-encapsulated bifunctional therapeutic; HER2-redirected T-cell engager with TLR7/8
ERBB2, TLR7, TLR8Phase 1Advanced Solid TumorsJun 2028
United ImmunityUI-102
TLR7/8 agonist encapsulated in Cholesteryl Pullulan Nanoparticle
TLR7, TLR8Phase 1Advanced CancerMar 2030
Xingchen PengHydroxychloroquine Sulfate
Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist
TLR7, TLR9Phase 1Radiation-induced Oral Mucositis–
InimmuneINI-4001
TLR7/8 agonist
TLR7, TLR8Phase 1Advanced Solid Tumor–

Conditions

Systemic Lupus Erythematosus (3) Breast Cancer (2) Diffuse Midline Glioma, H3 K27M-Mutant (2) Advanced Solid Tumor (2) Adenocarcinoma of the Pancreas (1) Breast Cancer Stage IIB (1) Graves Ophthalmopathy (1) Steatohepatitis, Nonalcoholic (1) Systemic Lupus Erythematosus (SLE) (1) Systematic Lupus Erythematosus (1) NSCLC (1) Advanced Melanoma (1)

Modalities

small molecule (11), mixed (9), protein or peptide (1)

Companies

Merck KGaA (2) West Virginia University (1) Abramson Cancer Center at Penn Medicine (1) National Taiwan University Hospital (1) Eikon Therapeutics (1) United Immunity (1) Beeline Medicines (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) OX2 Therapeutics (1) Medical University of South Carolina (1) NYU Langone Health (1) M.D. Anderson Cancer Center (1) Primmune Therapeutics (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) HighField Biopharmaceuticals (1) Ascendis Pharma Oncology Division (1) Xingchen Peng (1) University of Oxford (1) Bolt Biotherapeutics (1) Inimmune (1)

Related targets

TLR8 (11) TLR9 (7) ERBB2 (1) CLDN18 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.